Gross Law Corporations Associations 控告PepGen误导投资人了解其主要药物的安全和有效性。 Gross Law Firm sues PepGen for misleading investors on its lead drug's safety and effectiveness.

Gross Law Corporation已经对PepGen Inc.提起了集体诉讼,指控该公司有误导性投资者,指控该公司主要产品PGN-EDO51的有效性和安全性,以及该公司为林业发展局批准而进行的CONECT2研究是否充分。 The Gross Law Firm has initiated a class action lawsuit against PepGen Inc., accusing the company of misleading investors about the effectiveness and safety of its lead product, PGN-EDO51, and the adequacy of its CONNECT2 study for FDA approval. 诉讼的目的是为在类别期间购买股票的投资者追回损失。 The lawsuit aims to recover losses for investors who bought shares during the class period. 直到2025年8月8日,股东必须作为主要原告加入。 Shareholders have until August 8, 2025, to join as a lead plaintiff.